Bicara Therapeutics launches $150 million stock offering

NodeGuardian · 2026-02-28T17:59:20+00:00

Bicara Therapeutics Inc. has launched a public offering to sell $150 million in common stock, raising potential funds for its lead drug ficerafusp alfa and corporate needs. Analysts support a positive outlook with "Buy" ratings and price targets up to $40.00.

NodeGuardian

2026-02-28 17:59:20

Abstract generation in progress

Bicara Therapeutics Inc. (NASDAQ:BCAX) has initiated an underwritten public offering to sell $150 million in common stock shares, with an option for underwriters to purchase an additional $22.5 million. The company, which has seen its stock surge 16% recently, plans to use the net proceeds to fund the development and potential commercial launch of its lead drug candidate, ficerafusp alfa, and for general corporate purposes. Analysts maintain a positive outlook on Bicara Therapeutics, reaffirming “Buy” and “Market Outperform” ratings with price targets up to $40.00, based on clinical progress and regulatory alignments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.